Insmed, Inc.

How big is Insmed, Inc.?

As of Jun 18, Insmed, Inc. has a market capitalization of $19.05 billion, with net sales of $381.02 million and a net profit loss of $1.01 billion over the latest four quarters. Shareholder's funds are $285.38 million, and total assets amount to $2.03 billion.

As of Jun 18, Insmed, Inc. has a market capitalization of 19,048.33 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the company reported net sales of 381.02 million for the latest four quarters. However, it also experienced a net profit loss of 1,013.26 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 285.38 million and total assets amounting to 2,025.23 million.

What does Insmed, Inc. do?

Insmed, Inc. is a global biopharmaceutical company focused on developing treatments for rare diseases, with a market cap of approximately $19 billion. As of March 2025, it reported net sales of $93 million and a net loss of $257 million.

Overview:<BR>Insmed, Inc. is a global biopharmaceutical company operating in the Pharmaceuticals & Biotechnology industry, focusing on treatments for rare diseases.<BR><BR>Financial Snapshot:<BR>Net Sales: 93 Million (Quarterly Results - Mar 2025)<BR>Net Profit: -257 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 19,048.33 Million (Small Cap)<BR><BR>Key Metrics:<BR>Debt Equity: 0.79<BR>Return on Equity: -896.32%<BR>Price to Book: 192.10<BR><BR>Contact Details:<BR>Address: 700 US Highway 202/206, BRIDGEWATER NJ: 08807-1704<BR>Tel: 1 908 9779900<BR>Website: http://www.insmed.com/

Should I buy, sell or hold Insmed, Inc.?

Who are in the management team of Insmed, Inc.?

As of March 2022, Insmed, Inc.'s management team includes William Lewis as Chairman, President, and CEO, and David Brennan as Lead Independent Director, along with independent directors Carol Schafer, Alfred Altomari, Elizabeth Anderson, and Clarissa Desjardins.

As of March 2022, the management team of Insmed, Inc. includes Mr. William Lewis, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, Mr. David Brennan holds the position of Lead Independent Director. The board also comprises Ms. Carol Schafer, Mr. Alfred Altomari, Ms. Elizabeth Anderson, and Dr. Clarissa Desjardins, all of whom are independent directors.

Is Insmed, Inc. overvalued or undervalued?

As of February 22, 2019, Insmed, Inc. is considered risky and overvalued, with alarming negative financial ratios and inefficiencies, despite outperforming the S&P 500 year-to-date.

As of 22 February 2019, the valuation grade for Insmed, Inc. has moved from does not qualify to risky, indicating a significant change in its perceived risk profile. The company appears to be overvalued, with a Price to Book Value of 135.23 and negative EV to EBIT and EV to EBITDA ratios of -15.70 and -15.91, respectively. Additionally, the latest ROCE and ROE figures are alarming at -483.80% and -896.32%, respectively, suggesting severe inefficiencies in capital utilization and shareholder returns.<BR><BR>In comparison to its peers, Insmed, Inc. has a P/E ratio of -32.49, which is less favorable than Intra-Cellular Therapies, Inc. at -187.76 and Karuna Therapeutics, Inc. at -29.01. This places Insmed in a precarious position within the pharmaceuticals and biotechnology sector. Notably, Insmed has outperformed the S&P 500 over multiple periods, with a year-to-date return of 111.27% compared to the S&P 500's 12.22%, reinforcing the notion of overvaluation amidst its financial struggles.

Is Insmed, Inc. technically bullish or bearish?

As of July 21, 2025, Insmed, Inc. shows a bullish trend with strong MACD indicators, despite some bearish signals from the RSI, and has significantly outperformed the S&P 500 with a year-to-date return of 111.27%.

As of 21 July 2025, the technical trend for Insmed, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators from the MACD, which is bullish on both weekly and monthly time frames, and the daily moving averages also indicating bullish momentum. However, the RSI shows bearish signals on both weekly and monthly time frames, suggesting some weakness. The Bollinger Bands are mildly bullish weekly and bullish monthly, while the KST is bullish weekly but mildly bearish monthly. The Dow Theory indicates a mildly bullish stance on both time frames, and the OBV is bullish for both weekly and monthly periods.<BR><BR>In terms of performance, Insmed has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 111.27% compared to the S&P 500's 12.22%, and a 1-year return of 100.16% versus 17.14%. Overall, while there are some mixed signals, the prevailing trend is bullish.